Danaher (DHR) 44th Annual J.P. Morgan Healthcare Conference summary

Financial performance and outlook

• Fourth quarter 2025 results are expected to exceed prior expectations, with core growth at the high end of low single-digit guidance, driven by strong bioprocessing consumables and equipment sales.

• Adjusted EPS for 2025 is projected at the high end of $7.70–$7.80 guidance, supporting initial 2026 expectations of 3%–6% core revenue growth and high single-digit adjusted EPS growth.

• Estimated 2025 total revenue is ~$24.5B, with gross profit margin at 59.5% and adjusted operating profit margin at 28.6%.

• Operating cash flow exceeds $6B, with a net debt to adjusted EBITDA ratio of ~2.5x, providing capacity for further M&A.

• Free cash flow conversion remains strong, supporting top quartile EPS growth and compounding returns.

Market positioning and growth drivers

• Positioned in Biotechnology, Life Sciences, and Diagnostics, with over 15 leading operating companies and strong contributions from each segment.

• End markets benefit from secular growth drivers: aging population, shift to biologics, and adoption of new technologies like molecular diagnostics.

• Monoclonal antibodies and molecular diagnostics are experiencing double-digit growth since 2019, with Cytiva supporting over 90% of global mAb production volume.

• Recurring revenue streams account for ~80% of total revenue, driven by consumables and service contracts.

• Portfolio is aligned to long-term trends in healthcare innovation and diagnostics.

Segment performance and innovation

• Bioprocessing franchise generates over $6 billion, with 80% from monoclonal antibodies and over 90% market penetration in commercialized products.

• Life Sciences segment ($7.3 billion) features diversified end markets and over 60% recurring revenue, with ongoing margin expansion opportunities.

• Diagnostics segment ($10 billion) includes leading molecular diagnostics (Cepheid), specialty businesses, and strong growth in core lab diagnostics.

• Recent innovations include advanced mass spectrometers, scalable bioreactors, and high-sensitivity immunoassay analyzers, including the first automated high-throughput BD-Tau immunoassay for Alzheimer's research.

• New product revenue increased by 25% in the past year, driven by targeted innovation.